Navigation Links
A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
Date:6/12/2008

Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources

WALTHAM, Mass., June 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that is more effective than Roche's Xenical at inducing weight loss would earn a 40 percent patient share in the obesity drug market, according to surveyed primary care physicians. Although other efficacy measures-such as the effect on weight maintenance-are also important to prescribers, the biggest unmet need within this indication is a therapy that can consistently induce more than ten percent weight loss. The Food and Drug Administration currently requires that a drug elicit between five and ten percent weight loss to get approval.

The new report entitled Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety finds that Vivus's Qnexa will become Decision Resources' proprietary clinical gold standard by 2011 due to its competitive advantages in efficacy and delivery over the 2006 gold standard, Xenical. By 2016 however, Orexigen's Empatic will supersede Qnexa due to its advantage in safety. Both Empatic and Qnexa are fixed dose combinations of currently marketed central nervous system agents used for indications like epilepsy, alcohol dependence and depression.

"Phase II clinical trial data revealed that Qnexa caused a greater overall weight reduction compared with pooled data for Xenical after a 24-week treatment period," said Donny Wong, Ph.D., principal analyst at Decision Resources. "According to physicians we surveyed, Empatic's overall score for safety and tolerability is better, based on the perception that this combination agent is more conducive to longer-term treatment."

About the Report

Obesity: Current Pipeline Falls Short of Physicians' Expectations for Efficacy and Safety is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... April 22, 2017 , ... ... has named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of ... specializes in providing information destruction , recycling, and compliance services to ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
(Date:4/21/2017)... ... , ... The staff at Palm Beach Face is proud to announce that their practice founder, ... Set to take place on April 23rd, the London Marathon has a long tradition of ... part of team EMPOWER, raising money for the international charity, Smile Train. , ...
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... ... April 21, 2017 , ... Dudnyk has announced the launch of its ... that the full potential of specialty and orphan brands can only be achieved when ... , “The Unifying Effect is at the heart of a true partnership between our ...
Breaking Medicine News(10 mins):